Pharmaco-economic report, summary

Ulipristal (Esmya®) for the indication preoperative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Recommendation by Zorginstituut Nederland dated 25-03-2013, based on an evaluation by the WAR (Scientific Advisory Committee)

The Medical Products Committee (*Commissie Geneesmiddelen,* CG) has approved a pharmacoeconomic report for the medicine ulipristal (Esmya®). The following is a summary of the data supplied by the applicant. The final conclusion indicates the findings of the CG.

Economic evaluation
The economic evaluation was carried out using a cost-minimisation analysis. A decision tree was used. The study results, measured over a period of 3 years, were not extrapolated.

Comparative treatment
Ulipristal was compared with leuprorelin in the economic evaluation.

Assumptions
- Leuprorelin was administered to all patients allocated to this treatment by a GP (base-case)
- GP visits for diagnosis and prescription costs were the same for both treatments
- the administration of leuprorelin does not lead to productivity losses
- treatment with ulipristal or leuprorelin stops after 3 months or 12 weeks
- it takes 15 minutes for a home-care nurse to administer a GnRH-agonist

Effects
Not applicable.

Costs
Direct medical costs and direct non-medical costs were included in the base-case calculation. The average costs per patient were €442.86. The average incremental costs per patient are -€11.18 in comparison with the costs of leuprorelin.

Efficiency
The applicant reports that treatment with ulipristal, in comparison with leuprorelin, is cost-effective.

Final conclusion
The applicant claims that treatment with ulipristal is a cost-effective intervention for the preoperative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
The CG concludes that the cost-effectiveness of ulipristal in the preoperative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age has been sufficiently substantiated.